Disease-information
Montelukast is used to control and prevent symptoms caused by asthma. It is also used before exercise to prevent breathing problems during exercise (bronchospasm).Asthma Symptoms:Montelukast recommended dose is once a day in the evening and it’s important to take it regularly even when patient have no symptoms.Note: Montelukast is not a rescue medi...
Causes of chronic productive cough
A chronic ‘productive’ or ‘wet’ cough is a common presenting complaint for patients.The definition of a “chronic productive cough” was considered to be a cough regularly leading to the expectoration of sputum with the same duration as the standard definition of chronic cough i.e. more than 8 weeks....
Coronaviruses—by the very nature
of their RNA-based genome—have an intrinsically higher rate of mutation than
DNA-based viruses. That said, they manifest a lower rate of mutation than
influenza viruses due to the presence of genetic code for an enzyme that
corrects some transcription errors.
Mutations naturally arise during
viral replicati...
The COVID-19 Treatment Guidelines have been developed to
inform clinicians how to care for patients with COVID-19. Because clinical
information about the optimal management of COVID-19 is evolving quickly.
The recommendations in these Guidelines are based on scientific
evidence and expert opinion. Each recommendation includes two...
This guidance document is
intended for clinicians caring for COVID-19 patients during all phases of their
disease (i.e., screening to discharge). This update has been expanded to
meet the needs of front-line clinicians and promotes a multi-disciplinary
approach to care for patients with COVID-19, including those with mild,
moderate, severe, a...
In patients with severe or critical Coronavirus disease 2019 (COVID-19) manifestations, a thromboinflammatory syndrome, with diffuse microvascular thrombosis, is increasingly evident as the final step of pro-inflammatory cytokines storm. Actually, no proven effective therapies for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) i...
What do we know about this new
SARS-CoV-2 variant?
It’s been snappily named
VUI-202012/01 (the first “Variant Under Investigation” in December 2020) and is
defined by a set of 17 changes or mutations. One of the most significant is an
N501Y mutation in the spike protein that the virus uses to bind to the human
ACE2 receptor. Changes in this...
In a clinical trial of patients with COVID-19, monoclonal antibody were shown to reduce COVID-19-related
hospitalization or emergency room visits in patients at high risk for
disease progression within 28 days after treatment when compared to
placebo. The safety and effectiveness of this investigational therapy
for use in the treatment of C...
FDA Authorizes Monoclonal Antibody for Treatment of COVID-19. The U.S. FDA issued an emergency use authorization (EUA)
for the investigational monoclonal antibody therapy for
the treatment of mild-to-moderate COVID-19 in adult and pediatric
patients.
Dexamethasone : the first life-saving drug for COVID-19 patients
Clinical trials make it possible to
evaluate whether a treatment improves outcomes. Developing a hypothesis,
for example if treatment A is better than standard treatment B,
clinical trials enable understanding of the role of an intervention in
improving patient care. In the...
Baricitinib plus remdesivir was superior to remdesivir alone in reducing
recovery time and accelerating improvement in clinical status among
patients with Covid-19, notably among those receiving high-flow oxygen
or noninvasive ventilation. The combination was associated with fewer
serious adverse events.
The U.S. Food and Drug
Administration issued an emergency use authorization (EUA) for the drug
baricitinib, in combination with remdesivir, for the treatment of suspected or
laboratory confirmed COVID-19 in hospitalized adults and pediatric patients two
years of age or older requiring supplemental oxygen, invasive mechanical...
